Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

International Journal of Nanomedicine

Volumn 11, Issue , 2015, Pages 93-105

  Li, Xiaoyu ^a   Wu, Meiying ^a   Pan, Limin ^a   Shi, Jianlin ^a  

^a SHANGHAI INSTITUTE OF CERAMICS   (China)

Author keywords

Antiangiogenic agent; Drug delivery; Esoporous silica nanoparticles; Tumor vasculatures targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; COMBRETASTATIN A4; DOXORUBICIN; MESOPOROUS SILICA NANOPARTICLE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; COMBRETASTATIN A4 PHOSPHATE; DRUG CARRIER; NANOPARTICLE; OLIGOPEPTIDE; SILICON DIOXIDE; STILBENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HELA CELL LINE; HUMAN; HUMAN CELL; MALE; MOUSE; NEOPLASM; NONHUMAN; ORGAN DISTRIBUTION; SUSTAINED DRUG RELEASE; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; NEOPLASMS; PROCEDURES; TISSUE DISTRIBUTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; NANOPARTICLES; NEOPLASMS; OLIGOPEPTIDES; SILICON DIOXIDE; STILBENES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84952762147     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S81156     Document Type: Article

References (29)

1. He Q, Gao Y, Zhang L, et al. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials. 2011;32(30):7711-7720.
2. Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007;104(3):932-936.
3. Pearce TR, Shroff K, Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv Mater. 2012;24(28):3803-3822.
4. Chang DK, Chiu CY, Kuo SY, et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem. 2009;284(19):12905-12916.
5. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta. 2008;1778(4):854-863.
6. Mann AP, Tanaka T, Somasunderam A, Liu X, Gorenstein DG, Ferrari M. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater. 2011;23(36):H278-H282.
7. Gu G, Gao X, Hu Q, et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials. 2013;34(21):5138-5148.
8. Perabo F, Sharma S, Gierer R, et al. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin in urological malignancies. Indian J Cancer. 2001;38(1):1-7.
9. Shi S, Yang K, Hong H, et al. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials. 2013;34(12):3002-3009.
10. Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm. 2011;8(6):2291-2301.
11. Huang S, Shao K, Liu Y, et al. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano. 2013;7(3):2860-2871.
12. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Euro J Pharm Biopharm. 2010;74(3):467-473.
13. Xuan R, Lin L, Jiang D. [Vascular targeting agent-combretastatin A4]. Chinese Journal of New Drugs. 2007;16(17):1336-1341. Chinese.
14. Yang T, Wang Y, Li Z, et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine. 2012;8(1):81-92.
15. Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep. 2001;8(1):157-160.
16. Mitrus I, Sochanik A, Cichoń T, Szala S. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochim Pol. 2009;56(1):161-165.
17. Zhang F, Huang X, Zhu L, et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials. 2012;33(21):5414-5422.
18. Shenoi MM, Iltis I, Choi J, et al. Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm. 2013;10(5):1683-1694.
19. Chen Y, Chen H, Zeng D, et al. Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano. 2010;4(10):6001-6013.
20. Hauck TS, Ghazani AA, Chan WC. Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small. 2008;4(1):153-159.
21. Lebold T, Jung C, Michaelis J, Braüchle C. Nanostructured silica materials as drug-delivery systems for doxorubicin: single molecule and cellular studies. Nano Lett. 2009;9(8):2877-2883.
22. He Q, Gao Y, Zhang L, et al. One-pot self-assembly of mesoporous silica nanoparticle-based pH-responsive anti-cancer nano drug delivery system. J Mater Chem. 2011;21(39):15190-15192.
23. He Q, Shi J. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv Mater. 2014;26(3):391-411.
24. Chen Y, Chen H, Shi J. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater. 2013;25(23):3144-3176.
25. Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16(6):510-520.
26. Ma M, Chen H, Chen Y, et al. Au capped magnetic core/mesoporous silica shell nanoparticles for combined photothermo-/chemo-therapy and multimodal imaging. Biomaterials. 2012;33(3):989-998.
27. He Q, Zhang J, Chen F, Guo L, Zhu Z, Shi J. An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles. Biomaterials. 2010;31(30):7785-7796.
28. Gao Y, Yang C, Liu X, Ma R, Kong D, Shi L. A multifunctional nanocarrier based on nanogated mesoporous silica for enhanced tumor-specific uptake and intracellular delivery. Macromol Biosci. 2012;12(2):251-259.
29. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J Mater Chem. 2011;21(16):5845-5855.